Abstract
Chronic constipation is a common, persistent condition affecting many patients worldwide, presenting significant economic burden and resulting in substantial healthcare utilization. In addition to infrequent bowel movements, the definition of constipation includes excessive straining, a sense of incomplete evacuation, failed or lengthy attempts to defecate, use of digital manoeuvres for evacuation of stool, abdominal bloating, and hard consistency of stools. After excluding secondary causes of constipation, chronic idiopathic or primary constipation can be classified as functional defecation disorder, slow-transit constipation (STC), and constipation-predominant irritable bowel syndrome (IBS-C). These classifications are not mutually exclusive and significant overlap exists. Initial therapeutic approach to primary constipation, regardless of aetiology, consists of diet and lifestyle changes such as encouraging adequate fluid and fibre intake, regular exercise, and dietary modification. Laxatives are the mainstay of pharmacologic treatment for potential long-term therapy in patients who do not respond to lifestyle or dietary modification. After a failed empiric trial of laxatives, diagnostic testing is necessary to understand underlying anorectal and/or colonic pathophysiology. No single test provides a comprehensive assessment for primary constipation; therefore, multiple tests are used to provide complementary information to one another. Dyssynergic defecation, a functional defecation disorder, is an acquired behavioural disorder of defecation present in two-thirds of adult patients, where an inability to coordinate the abdominal, recto-anal, and pelvic floor muscles during attempted defecation exists. Biofeedback therapy is the mainstay treatment for dyssynergic defecation aimed at improving coordination of abdominal and anorectal muscles. A large percentage of patients with dyssynergic defecation also exhibit rectal hyposensitivity and may benefit from the addition of sensory retraining. Our understanding of the pathophysiology of STC is evolving. The advent of high-resolution colonic manometry allows for the improved identification of colonic motor patterns and may provide further insight into pathophysiological mechanisms. In a minority of cases of STC, identification of colonic neuropathy suggests a medically refractory condition, warranting consideration of colectomy. The pathophysiology of IBS-C is poorly understood with multiple etiological factors implicated. Pharmacological advances in the treatment of primary constipation have added therapeutic options to the armamentarium of this disorder. Drug development in the secretagogue, serotonergic prokinetic, and ileal bile acid transporter inhibition pathways has yielded current and future medical treatment options for primary chronic constipation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abdulla H, Yu S, Rattanakovit K, Badger C, Rao SS (2015) Small intestinal bacterial (SIBO) and fungal overgrowth (SIFO): a frequent unrecognized complication of colectomy. Am J Gastroenterol 110(Suppl 1s):S995
Arebi N, Kalli T, Howson W et al (2011) Systematic review of abdominal surgery for chronic idiopathic constipation. Colorectal Dis 13:1335–1343
Ashraf W, Park F, Lof J, Quigley EM (1995) Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther 9:639–647
Attaluri A, Jackson M, Paulson J, Rao SSC (2010) Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol 105:1407–1411
Attaluri A, Donahoe R, Valestin J, Brown K, Rao SS (2011) Randomized clinical trial: dried plums (prunes) vs. psyllium for constipation. Aliment Pharmacol Ther 33:822–828
Bang CS, Kim JH, Baik GH et al (2015) Mosapride treatment for functional dyspepsia: a meta-analysis. J Gastroenterol Hepatol 30:28–42
Bassil AK, Borman RA, Jarvi EM et al (2008) Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol 154:126–135
Bassotti G, Iantorno G, Fiorella S, Bustos-Fernandez L, Bilder CR (1999) Colonic motility in man: features in normal subjects and in patients with chronic idiopathic constipation. Am J Gastroenterol 94:1760–1770
Belsey J, Greenfield S, Candy D, Geraint M (2010) Systemic review: impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther 31:938–949
Bharucha AE, Wald A, Enck P et al (2006) Functional anorectal disorders. Gastroenterology 130:1510–1518
Bharucha AE, Dorn SD, Lembo A et al (2013) American Gastroenterological Association medical position statement on constipation. Gastroenterology 144:211–217
Busby RW, Bryant AP, Bartolini WP et al (2010) Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 649:328–335
Camilleri M (2015) Guanylate cyclase C agonists: emerging gastrointestinal therapies and actions. Gastroenterology 148:483–487
Camilleri M, Gores GJ (2015) Therapeutic targeting of bile acids. Am J Physiol Gastrointest Liver Physiol 309:G209–G215
Camilleri M, Vazquez-Roque MI, Burton D et al (2007) Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 19:30–38
Camilleri M et al (2010) Wireless pH motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. Neurogastroenterol Motil 22:874–882.e233
Castro J, Harrington AM, Hughes PA et al (2013) Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3′5′-monophosphate. Gastroenterology 145:1334–1346
Chang L, Lembo A, Sultan S (2014) American Gastroenterological Association Institute technical review on the pharmacological management of irritable bowel syndrome. Gastroenterology 147:1149–1172
Cheskin LJ, Kamal N, Crowell MD, Schuster MM, Whitehead WE (1995) Mechanisms of constipation in older persons and effects of fibre compared with placebo. J Am Geriatr Soc 43:666–669
Chevalier P, Lamotte M, Joseph A et al (2014) Inpatient costs associated with chronic constipation in Belgium: a retrospective database study. Neurogastroenterol Motil 26:368–376
Chey WD, Camilleri M, Chang L et al (2011) A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 106:1803–1812
Chey WD, Lembo AJ, Lavis BJ et al (2012) Linaclotide for irritable bowel syndrome with constipation: 26-week, randomized, double-blind, placebo-controlled trial to evaluate safety and efficacy. Am J Gastroenterol 107:1702–1712
Chey WD, Webster L, Sostek M et al (2014) Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 370:2387–2396
Chey WD, Kurlander J, Eswaran S (2015) Irritable bowel syndrome: a clinical review. JAMA 313:949–958
Chiarioni G, Whitehead WE, Pezza V et al (2006) Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology 130:657–664
Coss-Adame E, Rao SSC (2014) Brain and gut interactions in irritable bowel syndrome: new paradigm and new understandings. Curr Gastroenterol Rep 16:37
Crowell MD, Shetzline MA, Moses PL et al (2004) Enterochromaffin cells and 5-HT signalling in the pathophysiology of disorders of gastrointestinal function. Curr Opin Investig Drugs 5:55–60
Crowell MD, Harris L, Jones MP et al (2005) New insights into the pathophysiology of irritable bowel syndrome: implications for future treatments. Curr Gastroenterol Rep 7:272–279
Cummings JH, Macfarlane GT (1991) The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol 70:443–459
Dinning PG, Jones M, Hunt L et al (2011) Factor analysis identifies subgroups of constipation. World J Gastroenterol 17:1468–1474
Dinning PG, Wiklendt L, Maslen L et al (2014) Quantification of in vivo colonic motor patterns in healthy humans before and after a meal revealed by high resolution optic manometry. Neurogastroenterol Motil 26:1443–1457
Erdogan A, Rao SSC, Thiruvalyaru D et al (2016) Randomised clinical trial: mixed soluble/insoluble fibre vs. psyllium for chronic constipation. Aliment Pharmacol Ther 44:35–44
Fenn GC, Wilkinson PD, Lee CE, Akbar FA (1986) A general practice study of the efficacy of Regulan in functional constipation. Br J Clin Pract 40:192–197
Ford AC, Suares NC (2011) Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systemic review and meta-analysis. Gut 60:209–218
Goldberg M, Li P, Johanson JF et al (2010) Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther 32:1102–1112
Herve S et al (2004) Results of 24-h manometric recording of colonic motor activity with endoluminal instillation of bisacodyl in patients with severe chronic slow transit constipation. Neurogastroenterol Motil 16:397–402
Herz MJ, Kahan E, Zalevski S et al (1996) Constipation: a different entity for patients and doctors. Fam Pract 13:156–159
Heymen S, Wexner SD, Vickers D et al (1999) Prospective, randomized trial comparing for biofeedback techniques for patients with constipation. Dis Colon Rectum 42:1388–1393
Higgins PD, Johanson JF (2004) Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 99:750–759
Jarmuz A, Zielinska M, Storr M, Fichna J (2015) Emerging treatments in neurogastroenterology: perspectives of guanylate cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases. Neurogastroenterol Motil 27:1057–1068
Kamm MA, Mueller-Lissner S, Wald A et al (2011) Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol 9:577–583
Kassinen A, Krogius-Kurikka L, Makivuokko H et al (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133:24–33
Lee YY, Erdogan A, Rao SS (2013) High resolution and high definition anorectal manometry and pressure topography: diagnostic advance or a new kid on the block? Curr Gastroenterol Rep 15:360
Lee-Robichaud H, Thomas K, Morgan J et al (2010) Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev 7:CD007570
Lees NP, Hodson P, Hill J et al (2004) Long-term results of the antegrade continent enema procedure for constipation in adults. Colorectal Dis 6:362–368
Lembo A, Johanson JF, Parkman HP et al (2011) Long-term safety and effectiveness of lubiprostone, a chloride channel (CIC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci 56:2639–2645
Levitt MD, Furne JK, Kuskowski M et al (2006) Stability of human methanogenic flora over 35 years and a review of insights obtained from breath methane measurements. Clin Gastroenterol Hepatol 4:123–129
Longstreth GF, Thompson WG, Chey WD et al (2006) Functional bowel disorders. Gastroenterology 131:688
Lui Z, Sakakibara R, Odaka T et al (2005) Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 20:680–686
Lyford GL, He CL, Soffer E et al (2002) Pan-colonic decrease in interstitial cells of Cajal in patients with slow transit constipation. Gut 51:496–501
Manini ML, Camilleri M, Goldberg M et al (2010) Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 22:42–49
Mayer EA, Tillisch K (2011) The brain-gut axis in abdominal pain syndromes. Annu Rev Med 62:381–396
Mertz H, Naliboff B, Munakata J et al (1995) Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 109:40–52
Miner PB et al (2014) Plecanatide, a novel uroguanylin analog: a 12-week, randomized, double-blind, placebo-controlled, dose ranging trial to evaluate efficacy and safety in patients with irritable bowel syndrome with constipation (IBS-C). Am J Gastroenterol 109:S541
Mugie SM, Benninga MA, DiLorenzo C (2011) Epidemiology of constipation in children and adults: a systemic review. Best Pract Res Clin Gastroenterol 25:3–18
Papachrysostomou M, Smith AN (1994) Effects of biofeedback on obstructive defecation – reconditioning of the defecation reflex? Gut 35:242–245
Pare P, Ferrazzi S, Thompson D et al (2001) An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 96:3130–3137
Pemberton JH, Rath DM, Ilstrup DM (1991) Evaluation and surgical treatment of severe chronic constipation. Ann Surg 214:403–413
Pimental M, Lin HC, Enayati P et al (2006) Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol 290:G1089–G1095
Pimental M, Gunsalus RP, Rao SSC et al (2012) Methanogens in human health and disease. Am J Gastroenterol Suppl 1:28–33
Posserud I, Stotzer P, Björnsson E, Abrahamsson H, Simrén M (2007) Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 56:802–808
Preston DM, Lennard-Jones JE (1986) Severe colonic constipation of young women: “idiopathic slow transit constipation”. Gut 27:41–48
Quigley EMM (2011) Cisapride: what can we learn from the rise and fall of a prokinetic? J Dig Dis 12:147–156
Quigley EMM, Neshatian L (2016) Advancing treatment options for chronic idiopathic constipation. Expert Opin Pharmacother 17:501–511
Raizada V, Bhargava V, Karsten A, Mittal RK (2011) Functional morphology of anal sphincter complex unveiled by high definition anal manometry and three dimensional ultrasound imaging. Neurogastroenterol Motil 23:1013–1019.e460
Rao SS (2008) Dyssynergic defecation and biofeedback therapy. Gastroenterol Clin North Am 37:569–586
Rao SS, Enck P, Loening-Baucke V (1997) Biofeedback therapy for defecation disorders. Dig Dis 15(Suppl 1):78–92
Rao SS, Welcher KD, Leistikow JS (1998a) Obstructive defecation: a failure of rectoanal coordination. Am J Gastroenterol 93:1042–1050
Rao SS, Ozturk R, De Ocampo S, Stessman M (1998b) Pathophysiology and role of biofeedback therapy in solitary rectal ulcer syndrome. Am J Gastroenterol 101:613–618
Rao SS, Tuteja AK, Vellema T et al (2004) Dyssynergic defecation: demographics, symptoms, stool patterns, and quality of life. J Clin Gastroenterol 38:680–685
Rao SS, Ozturk R, Lain L (2005a) Clinical utility of diagnostic tests for constipation in adults: a systemic review. Am J Gastroenterol 100:1605–1615
Rao SS, Kinkade K, Miller MJ et al (2005b) Randomized controlled trial of long term outcome of biofeedback therapy (BT) for dyssynergic defecation. Am J Gastroenterol 100:386
Rao SSC, Kavlock R, Rao S (2006) Influence of body position and stool characteristics on defecation in humans. Am J Gastroenterol 101:2790–2796
Rao SS et al (2007a) Psychological profiles and quality of life differ between patients with dyssynergia and those with slow transit constipation. J Psychosom Res 63:441–449
Rao SS, Seaton K, Miller M et al (2007b) Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol 5:331–338
Rao S, Lembo AJ, Shiff SJ et al (2012) A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 107:1714–1724
Rao SS, Yu S, Fedewa A (2015) A systemic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther 41:1256–1270
Rattanakovit K, Rao SS, Amieva M, Mack A, Dewitt A (2015) Dyssynergia or no dyssynergia: phenotypic categorization of constipated patients with high-resolution anorectal manometry (HRAM). Am J Gastroenterol 110(Suppl 1s):S593
Ravi K et al (2010) Phenotypic variation of colonic motor functions in chronic constipation. Gastroenterology 138:89–97
Reiner CS et al (2011) MR defecography in patients with dyssynergic defecation: spectrum of imaging findings and diagnostic value. Br J Radiol 84:136–144
Remes-Troche JM, Rao SS (2006) Diagnostic testing in patients with chronic constipation. Curr Gastroenterol Rep 8:416–424
Ringel Y, Carroll IM (2009) Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am 19:141–150
Sachdev AH, Pimental M (2012) Antibiotics for irritable bowel syndrome: rationale and current evidence. Curr Gastroenterol Rep 14:439–445
Sethi S, Mikami S, Leclair J et al (2014) Inpatient burden of constipation in the United States: an analysis of national trends in the United States from 1997 to 2010. Am J Gastroenterol 109:250–256
Shepherd SJ, Lomer MC, Gibson PR (2013) Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol 108:707–717
Shin A, Camilleri M, Kolar G et al (2014) Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 39:239–253
Simren M, Bajor A, Gillberg PG et al (2011) Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation-a double-blind study. Aliment Pharmacol Ther 34:41–50
Singh G, Lingala V, Wang H et al (2007) Use of health care resources and cost of care for adults with constipation. Clin Gastroenterol Hepatol 5:1053–1058
Singh S, Heady S, Coss-Adame E, Rao SS (2013) Clinical utility of colonic manometry in slow-transit constipation. Neurogastroenterol Motil 25:487–495
Soares AC, Lederman HM, Fagundes-Neto U (2005) Breath methane associated with slow colonic transit time in children with chronic constipation. J Clin Gastroenterol 39:512–515
Sommers T, Corban C, Sengupta N et al (2015) Emergency department burden of constipation in the United States from 2006 to 2011. Am J Gastroenterol 110:572–579
Spiller R, Lam C (2012) An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil 18:258–268
Stephen AM, Cummings JH (1980) Mechanism of action of dietary fibre in the human colon. Nature 284:283–284
Suares NC, Ford AC (2011) Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systemic review and meta-analysis. Am J Gastroenterol 106:1582–1591
Tack J, Camilleri M, Chang L et al (2012) Systemic review: cardiovascular safety profile of 5HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 35:745–767
Thompson WG, Longstreth GF, Drossman DA et al (1999) Functional bowel disorders and functional abdominal pain. Gut 45:1143–1147
Tomlin J, Read NW (1988) The relation between bacterial degradation of viscous polysaccharides and stool output in human beings. Br J Nutr 60:467–475
Xiao ZL, Pricolo V, Biancani P, Behar J (2005) Role of progesterone signalling in the regulation of G-protein levels in female chronic constipation. Gastroenterology 128:667–675
Yu SW, Rattanakovit K, Mack A, Rao SS (2015) Is gastroparesis a pan-enteric neuropathic disorder: investigation with wireless motility capsule? Gastroenterology 148(Suppl 1):S516–S517
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing AG
About this chapter
Cite this chapter
Sharma, A., Rao, S. (2016). Constipation: Pathophysiology and Current Therapeutic Approaches. In: Greenwood-Van Meerveld, B. (eds) Gastrointestinal Pharmacology . Handbook of Experimental Pharmacology, vol 239. Springer, Cham. https://doi.org/10.1007/164_2016_111
Download citation
DOI: https://doi.org/10.1007/164_2016_111
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56359-6
Online ISBN: 978-3-319-56360-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)